1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

Thumbnail for Slowing Mortality Gains in Multiple Myeloma Despite Novel Therapies: Global and SDI-Based Disparities From the GBD 2023 Study (1990-2023)

MM - 207

Slowing Mortality Gains in Multiple Myeloma Despite Novel Therapies: Global and SDI-Based Disparities From the GBD 2023 Study (1990-2023)

Tapan Giri

Poster Presenter: Tapan Giri

MM - 218

Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis

Giada Bianchi

Poster Presenter: Giada Bianchi

Thumbnail for Understanding the Symptom Burden and Health-Related Quality of Life Among Black Patients With Multiple Myeloma: A Retrospective Analysis of Patient-Reported Data

MM - 220

Understanding the Symptom Burden and Health-Related Quality of Life Among Black Patients With Multiple Myeloma: A Retrospective Analysis of Patient-Reported Data

Osborn Owusu Ansah

Poster Presenter: Osborn Owusu Ansah

$Thumbnail for Outcomes and Toxicity of CAR T-Cell Therapy in Patients With Renal Impairment: A Propensity Score-Matched Analysis in Relapsed/Refractory Multiple Myeloma$

MM - 224

Outcomes and Toxicity of CAR T-Cell Therapy in Patients With Renal Impairment: A Propensity Score-Matched Analysis in Relapsed/Refractory Multiple Myeloma

Anushareddy Muddasani

Poster Presenter: Anushareddy Muddasani

Thumbnail for Early Real-World Utilisation, Resource Use, and In-Hospital Outcomes of BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A National Inpatient Analysis, 2022-2023

MM - 225

Early Real-World Utilisation, Resource Use, and In-Hospital Outcomes of BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A National Inpatient Analysis, 2022-2023

Aniqa Baloch

Poster Presenter: Aniqa Baloch

$Thumbnail for Safety and Effectiveness of Bispecific Antibody Therapy Across the Spectrum of Kidney Function in Relapsed/Refractory Multiple Myeloma$

MM - 226

Safety and Effectiveness of Bispecific Antibody Therapy Across the Spectrum of Kidney Function in Relapsed/Refractory Multiple Myeloma

Anushareddy Muddasani

Poster Presenter: Anushareddy Muddasani

MM - 251

Distinct Inpatient and Post-Discharge Risk States Defined by AKI and Acute Dialysis in Multiple Myeloma Hospitalizations

Woo Joo Lee

Poster Presenter: Woo Joo Lee

$Thumbnail for Reduced-Frequency Dosing of FDA-Approved Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review of Maintaining Efficacy While Reducing Infection-Related Toxicity$

MM - 263

Reduced-Frequency Dosing of FDA-Approved Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review of Maintaining Efficacy While Reducing Infection-Related Toxicity

Mahboob Younus Shaik

Poster Presenter: Mahboob Younus Shaik

Thumbnail for Cardiovascular Adverse Events Associated With Immune Checkpoint Inhibitors in Hematologic Malignancies: A Systematic Review of Recent Clinical Studies

MM - 265

Cardiovascular Adverse Events Associated With Immune Checkpoint Inhibitors in Hematologic Malignancies: A Systematic Review of Recent Clinical Studies

Yusuf Shahab

Poster Presenter: Yusuf Shahab